Abstract
Organic cation transporters (OCTs) and organic anion transporters (OATs) (SLC22A family) play crucial roles in the renal secretion of various drugs. Messengar ribonucleic acid (mRNA) expression of transporters can be a key factor regulating interindividual differences in drug pharmacokinetics. However, the source of variations in mRNA levels of transporters is unclear. In this study, we focused on single nucleotide polymorphisms (SNP) in the promoter region [regulatory SNPs (rSNPs)] as candidates for the factor regulating mRNA levels of SLC22A. We sequenced the promoter regions of OCT2 and OAT1–4 in 63 patients and investigated the effects of the identified rSNPs on transcriptional activities and mRNA expression. In the OCT2 promoter region, one deletion polymorphism (−578_−576delAAG) was identified; −578_−576delAAG significantly reduced OCT2 promoter activity (p < 0.05), and carriers of −578_−576delAAG tend to have lower OCT2 mRNA levels, but the difference is not significant. There was no rSNP in the OAT1 and OAT2 genes. The five rSNPs of OAT3 and one rSNP of OAT4 were unlikely to influence mRNA expression and promoter activity. This is the first study to investigate the influences of rSNPs on mRNA expression of SLC22A in the kidney and to identify a regulatory polymorphism affecting OCT2 promoter activity.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Asaka J, Terada T, Ogasawara K, Katsura T, Inui K (2007) Characterization of the Basal promoter element of human organic cation transporter 2 gene. J Pharmacol Exp Ther 321:684–689
Bhatnagar V, Xu G, Hamilton BA, Truong DM, Eraly SA, Wu W, Nigam SK (2006) Analyses of 5′ regulatory region polymorphisms in human SLC22A6 (OAT1) and SLC22A8 (OAT3). J Hum Genet 51:575–580
Buckland PR (2006) The importance and identification of regulatory polymorphisms and their mechanisms of action. Biochim Biophys Acta 1762:17–28
Buist SC, Cherrington NJ, Choudhuri S, Hartley DP, Klaassen CD (2002) Gender-specific and developmental influences on the expression of rat organic anion transporters. J Pharmacol Exp Ther 301:145–151
Burckhardt BC, Burckhardt G (2003) Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol 146:95–158
de Jong FA, de Jonge MJ, Verweij J, Mathijssen RH (2006) Role of pharmacogenetics in irinotecan therapy. Cancer Lett 234:90–106
Deguchi T, Takemoto M, Uehara N, Lindup WE, Suenaga A, Otagiri M (2005) Renal clearance of endogenous hippurate correlates with expression levels of renal organic anion transporters in uremic rats. J Pharmacol Exp Ther 314:932–938
Inui K, Masuda S, Saito H (2000) Cellular and molecular aspects of drug transport in the kidney. Kidney Int 58:944–958
Ji L, Masuda S, Saito H, Inui K (2002) Down-regulation of rat organic cation transporter rOCT2 by 5/6 nephrectomy. Kidney Int 62:514–524
Kajiwara M, Terada T, Asaka J, Ogasawara K, Katsura T, Ogawa O, Fukatsu A, Doi T, Inui K (2007) Critical roles of Sp1 in gene expression of human and rat H+/organic cation antiporter MATE1. Am J Physiol Renal Physiol 293:F1564–F1570
Kikuchi R, Kusuhara H, Hattori N, Shiota K, Kim I, Gonzalez FJ, Sugiyama Y (2006) Regulation of the expression of human organic anion transporter 3 by hepatocyte nuclear factor 1α/β and DNA methylation. Mol Pharmacol 70:887–896
Koepsell H, Endou H (2004) The SLC22 drug transporter family. Pflügers Arch 447:666–676
Koepsell H, Lips K, Volk C (2007) Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 24:1227–1251
Monica Torres A, Mac Laughlin M, Muller A, Brandoni A, Anzai N, Endou H (2005) Altered renal elimination of organic anions in rats with chronic renal failure. Biochim Biophys Acta 1740:29–37
Motohashi H, Sakurai Y, Saito H, Masuda S, Urakami Y, Goto M, Fukatsu A, Ogawa O, Inui K (2002) Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol 13:866–874
Ogasawara K, Terada T, Asaka J, Katsura T, Inui K (2006) Human organic anion transporter 3 gene is regulated constitutively and inducibly via a cAMP-response element. J Pharmacol Exp Ther 319:317–322
Ogasawara K, Terada T, Asaka J, Katsura T, Inui K (2007) Hepatocyte nuclear factor-4α regulates the human organic anion transporter 1 gene in the kidney. Am J Physiol Renal Physiol 292:F1819–F1826
Peltekova VD, Wintle RF, Rubin LA, Amos CI, Huang Q, Gu X, Newman B, Van Oene M, Cescon D, Greenberg G, Griffiths AM, St George-Hyslop PH, Siminovitch KA (2004) Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet 36:471–475
Popowski K, Eloranta JJ, Saborowski M, Fried M, Meier PJ, Kullak-Ublick GA (2005) The human organic anion transporter 2 gene is transactivated by hepatocyte nuclear factor-4α and suppressed by bile acids. Mol Pharmacol 67:1629–1638
Rizwan AN, Burckhardt G (2007) Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles. Pharm Res 24:450–470
Saji T, Kikuchi R, Kusuhara H, Kim I, Gonzalez FJ, Sugiyama Y (2008) Transcriptional regulation of human and mouse organic anion transporter 1 by hepatocyte nuclear factor 1α/β. J Pharmacol Exp Ther 324:784–790
Sakurai Y, Motohashi H, Ueo H, Masuda S, Saito H, Okuda M, Mori N, Matsuura M, Doi T, Fukatsu A, Ogawa O, Inui K (2004) Expression levels of renal organic anion transporters (OATs) and their correlation with anionic drug excretion in patients with renal diseases. Pharm Res 21:61–67
Sakurai Y, Motohashi H, Ogasawara K, Terada T, Masuda S, Katsura T, Mori N, Matsuura M, Doi T, Fukatsu A, Inui K (2005) Pharmacokinetic significance of renal OAT3 (SLC22A8) for anionic drug elimination in patients with mesangial proliferative glomerulonephritis. Pharm Res 22:2016–2022
Sugatani J, Yamakawa K, Yoshinari K, Machida T, Takagi H, Mori M, Kakizaki S, Sueyoshi T, Negishi M, Miwa M (2002) Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia. Biochem Biophys Res Commun 292:492–497
Terada T, Inui K (2007) Gene expression and regulation of drug transporters in the intestine and kidney. Biochem Pharmacol 73:440–449
Thomas MC, Tikellis C, Burns WC, Thallas V, Forbes JM, Cao Z, Osicka TM, Russo LM, Jerums G, Ghabrial H, Cooper ME, Kantharidis P (2003) Reduced tubular cation transport in diabetes: prevented by ACE inhibition. Kidney Int 63:2152–2161
Tokuhiro S, Yamada R, Chang X, Suzuki A, Kochi Y, Sawada T, Suzuki M, Nagasaki M, Ohtsuki M, Ono M, Furukawa H, Nagashima M, Yoshino S, Mabuchi A, Sekine A, Saito S, Takahashi A, Tsunoda T, Nakamura Y, Yamamoto K (2003) An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat Genet 35:341–348
Urakami Y, Nakamura N, Takahashi K, Okuda M, Saito H, Hashimoto Y, Inui K (1999) Gender differences in expression of organic cation transporter OCT2 in rat kidney. FEBS Lett 461:339–342
Wang X, Tomso DJ, Liu X, Bell DA (2005) Single nucleotide polymorphism in transcriptional regulatory regions and expression of environmentally responsive genes. Toxicol Appl Pharmacol 207:84–90
Acknowledgments
This work was supported in part by the Twenty First Century COE program “Knowledge Information Infrastructure for Genome Science,” a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and a Grant-in-Aid for Research on Advanced Medical Technology from the Ministry of Health, Labor and Welfare of Japan. KO is supported as a research assistant by the Twenty First Century COE program “Knowledge Information Infrastructure for Genome Science.”
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ogasawara, K., Terada, T., Motohashi, H. et al. Analysis of regulatory polymorphisms in organic ion transporter genes (SLC22A) in the kidney. J Hum Genet 53, 607–614 (2008). https://doi.org/10.1007/s10038-008-0288-9
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1007/s10038-008-0288-9
Keywords
This article is cited by
-
Polymorphism of Organic Cation Transporter 2 Improves Glucose-Lowering Effect of Metformin via Influencing Its Pharmacokinetics in Chinese Type 2 Diabetic Patients
Molecular Diagnosis & Therapy (2015)
-
Association of Intergenic Polymorphism of Organic Anion Transporter 1 and 3 Genes With Hypertension and Blood Pressure Response to Hydrochlorothiazide
American Journal of Hypertension (2011)
